These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8301118)

  • 1. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells.
    Nygard NR; Giacoletto KS; Bono C; Gorka J; Kompelli S; Schwartz BD
    J Immunol; 1994 Feb; 152(3):1082-93. PubMed ID: 8301118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells.
    Ceppellini R; Frumento G; Ferrara GB; Tosi R; Chersi A; Pernis B
    Nature; 1989 Jun; 339(6223):392-4. PubMed ID: 2786148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR.
    Roche PA; Cresswell P
    J Immunol; 1990 Mar; 144(5):1849-56. PubMed ID: 2307844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct binding of thymopentin to surface class II major histocompatibility complex in living cells.
    Liu Z; Wang J; Wang E
    J Phys Chem B; 2010 Jan; 114(1):638-42. PubMed ID: 20000455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells.
    Monji T; Pious D
    J Immunol; 1997 Apr; 158(7):3155-64. PubMed ID: 9120269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding.
    Roche PA; Cresswell P
    Nature; 1990 Jun; 345(6276):615-8. PubMed ID: 2190094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of the MHC class II molecules on B cells by peptide ligands.
    Agrawal B; Fraga E; Kane K; Singh B
    J Immunol; 1994 Feb; 152(3):965-75. PubMed ID: 8301149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
    Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
    J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular basis for detection of infectious agents].
    Siegrist CA
    Schweiz Med Wochenschr; 1996 Feb; 126(7):246-54. PubMed ID: 8720322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral peptide specific induction of MHC class II expression by murine T cell clones.
    Thomas DB; Smith CA; Graham CM
    J Immunol; 1996 Sep; 157(6):2386-94. PubMed ID: 8805637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inefficient peptide binding by cell-surface class II MHC molecules.
    Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
    Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular mechanisms of exogenous peptide binding to HLA class II molecules in B cells.
    Frumento G; de Totero D; Ferrara GB; Chersi A; Pernis B
    Cell Immunol; 1994 Apr; 155(1):1-10. PubMed ID: 8168138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HLA system, antigen processing and presentation.
    Krensky AM
    Kidney Int Suppl; 1997 Mar; 58():S2-7. PubMed ID: 9067934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody recognition of an immunogenic influenza hemagglutinin-human leukocyte antigen class II complex.
    Nygard NR; Bono C; Brown LR; Gorka J; Giacoletto KS; Schaiff WT; Graham MB; McCourt DW; Kabeer M; Braciale VL
    J Exp Med; 1991 Jul; 174(1):243-51. PubMed ID: 2056278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of HLA-DRA1*0101/DRB1*0401 molecules expressed in Drosophila melanogaster cells.
    Hansen BE; Andersson EC; Madsen LS; Engberg J; Søndergaard L; Svejgaard A; Fugger L
    Tissue Antigens; 1998 Feb; 51(2):119-28. PubMed ID: 9510368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular transport and peptide binding properties of HLA class II glycoproteins.
    Cresswell P; Avva RR; Davis JE; Lamb CA; Riberdy JM; Roche PA
    Semin Immunol; 1990 Jul; 2(4):273-80. PubMed ID: 2104276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes.
    Callahan KM; Rowell JF; Soloski MJ; Machamer CE; Siliciano RF
    J Immunol; 1993 Sep; 151(6):2928-42. PubMed ID: 8376762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.